ADC Therapeutics Introduces Inducement Grants for New Employees to Boost Engagement and Performance

ADC Therapeutics Introduces New Employee Inducement Grants

On October 1, 2025, ADC Therapeutics SA (NYSE: ADCT), renowned for its pioneering work in antibody-drug conjugates (ADCs), announced a strategic initiative to foster employee engagement and performance. The company granted options to purchase a total of 162,000 shares of its common stock to four new employees as part of its Inducement Plan. This move, designed to attract top talent, reflects ADC's commitment to rewarding efforts that contribute significantly to the company's success in the competitive pharmaceutical sector.

The Grants were made with the approval of the Compensation Committee under the company's established policies, ensuring adherence to the NYSE’s inducement exemption under Rule 303A.08. This regulation allows companies to incentivize new hires with stock options, thereby strengthening ties between the employees' potential contributions and their own financial incentives. Each Grant will vest incrementally—25% on the first anniversary and thereafter 1/48th monthly—culminating in full vesting by the fourth anniversary, contingent on continued employment.

ADC Therapeutics stands at the forefront of developing innovative treatments for cancers, specifically leveraging the efficacy of ADC technology. Their flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), has garnered accelerated approval from the FDA and has seen conditional acceptance from the European Commission for treating patients with relapsed or refractory diffuse large B-cell lymphoma after multiple systemic therapy failures. ZYNLONTA is not just a product; it embodies ADC Therapeutics' mission to revolutionize cancer treatment and improve patient outcomes through precision medicine.

In addition to ZYNLONTA, ADC Therapeutics is advancing towards developing next-generation PSMA-targeting ADCs, further consolidating its expertise in this vital area of medical research. With capabilities that span from clinical trials to manufacturing and commercialization, ADC Therapeutics is firmly positioned to continue its trajectory of growth and innovation within the biopharmaceutical landscape.

As ADC Therapeutics seeks to expand its footprint in the oncology market, the importance of the Inducement Plan is twofold. Firstly, it serves as a tool for attracting skilled professionals who can contribute to the company's innovative endeavors. Secondly, it reinforces a performance-driven culture, ensuring that employees are aligned with the company's goals and motivated to excel in their roles.

The forward-looking statements contained in the release underscore the inherent risks involved in the pharmaceutical industry, including regulatory hurdles and market competition. Nevertheless, ADC Therapeutics' proactive approach to employee engagement through incentive grants is a strategic step towards building a resilient workforce capable of navigating these challenges.

As ADC Therapeutics continues to explore opportunities for expansion and innovation, the focus on human capital through initiatives like these grants showcases a commitment not only to product excellence but also to cultivating an empowered and dedicated team. With headquarters in Lausanne, Switzerland, and operations spanning London and New Jersey, ADC Therapeutics reflects a global commitment to advancing cancer treatment through its innovative technologies.

For further information, consider visiting ADC Therapeutics’ official website or following them on LinkedIn. This engagement will provide insights into their ongoing developments and contributions to the field of oncology.